8-K: Assertio Holdings Faces Potential Delisting from Nasdaq Due to Low Share Price

Assertio Holdings, Inc. received a notification from Nasdaq regarding potential delisting due to its common stock price falling below the required $1.00 per share for an extended period.

Summary

• Assertio Holdings, Inc. has been notified by Nasdaq that it is not in compliance with the minimum $1.00 per share requirement for continued listing.
• The notification was received on January 22, 2025, after the company's stock price remained below $1.00 for 32 consecutive business days.
• This could lead to the delisting of the company's common stock from the Nasdaq Capital Market.
• Assertio has a 180-day period, until July 21, 2025, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
• The company may be eligible for an additional 180-day compliance period if it fails to meet the initial deadline.
• Assertio intends to monitor its stock price and consider options to regain compliance, but there is no guarantee it will succeed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the potential delisting from Nasdaq, indicating financial instability and uncertainty for investors.

Positives

• Assertio has a grace period of 180 days to regain compliance with Nasdaq's listing requirements.
• The company may be eligible for an additional 180-day period to regain compliance if needed.
• Assertio intends to actively monitor the situation and consider options to improve its stock price.

Negatives

• Assertio's common stock is at risk of being delisted from the Nasdaq Capital Market.
• The company's stock price has been below $1.00 for an extended period, indicating potential financial challenges.
• There is no guarantee that Assertio will be able to regain compliance with the Bid Price Rule.

Risks

• Failure to regain compliance with Nasdaq's listing requirements could lead to delisting, which may negatively impact investor confidence and the company's ability to raise capital.
• The company's stock price may remain depressed, making it difficult to achieve the required $1.00 per share threshold.
• The company's efforts to regain compliance may not be successful, regardless of the strategies employed.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule.

Industry Context

Many pharmaceutical companies, especially smaller ones, face challenges in maintaining stock prices due to factors like drug development setbacks, regulatory hurdles, and market competition. Delisting warnings are not uncommon in this sector.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Assertio will monitor its stock price.
• Assertio will consider options to regain compliance with Nasdaq listing rules.

Key Dates